Loading...
XSHE
002099
Market cap1.22bUSD
Jul 10, Last price  
5.24CNY
1D
2.34%
1Q
-28.32%
Jan 2017
-38.21%
IPO
92.29%
Name

Zhejiang Hisoar Pharmaceutical Co Ltd

Chart & Performance

D1W1MN
XSHE:002099 chart
P/E
—
P/S
4.56
EPS
—
Div Yield, %
—
Shrs. gr., 5y
-1.28%
Rev. gr., 5y
-5.52%
Revenues
1.86b
-4.01%
770,205,8801,034,886,0221,062,995,967893,369,0471,074,589,2591,298,437,7631,145,374,3761,160,690,6961,319,135,7362,464,495,5332,433,862,0702,308,922,1692,718,608,7962,941,412,7702,471,386,6252,484,828,4372,704,144,0452,171,886,8681,938,465,6571,860,693,572
Net income
-91m
L-72.42%
50,939,76331,050,88225,597,25330,301,75885,628,270105,064,38622,780,426-82,106,90053,519,260516,587,196225,018,253342,217,162605,003,825770,782,189319,715,25095,229,60888,013,730-420,055,855-330,267,195-91,075,549
CFO
-60m
L
61,882,54451,140,58830,607,75998,380,566180,879,96592,619,740180,727,34160,850,636191,561,807462,163,337629,417,200102,676,414791,449,237612,399,095533,869,722102,360,758116,092,038240,536,591174,834,870-59,678,368
Dividend
May 24, 20230.05 CNY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Zhejiang Hisoar Pharmaceutical Co., Ltd. is a pharmaceutical enterprise that specializes in the manufacturing and global distribution of fine chemicals and specialized active pharmaceutical ingredients (APIs). Its diverse product portfolio encompasses materials used in the production of antibiotics, antiviral medications, cardiovascular drugs, and glucose-reducing agents, among others. Beyond these core APIs, the company also supplies pharmaceutical intermediates and provides customized processing services. Key products include clindamycin, the 4-AA Iso-carbapenem series, thiamphenicol, florfenicol, and voglibose. A significant portion of its output is destined for international markets through exports. Established in 1966, the company maintains its operational headquarters in Taizhou, China.
URL
https://www.hisoar.com/
IPO date
Dec 26, 2006
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT